Wednesday, August 07, 2024

Study Finds GLP-1s Are Effectively Over-the-Counter obesity Drugs in Online Grey Market. So why not make it a legal over-the-counter drug!

Food for thought! 

As an over-the-counter drug it would also immediately lower costs considerable, how nice inflationary times!

I might be wrong, but the known side effects of semaglutide seem to be quite manageable for most adults. Government paternalism may not be needed!

What about overdosing? Well, we allow adults to overdose on alcohol!

Which risks are greater fake drugs sold e.g. over the Internet by a dubious vendor or semaglutide available as an over-the-counter drug from a drug store?

"A qualitative study published August 2 in the Journal of the American Medical Association reported that “semaglutide products are actively being sold without prescription by illegal online pharmacies, with vendors shipping unregistered and falsified products.” Some of these products were knockoffs of brands such as Ozempic and Wegovy and contained impurities, some of which were toxic. ...
The researchers found that about 42 percent of online vendors were operating without a valid license or selling these drugs without a prescription. ..."

"... This qualitative study found that semaglutide products are actively being sold without prescription by illegal online pharmacies, with vendors shipping unregistered and falsified products. Two websites evaluated were sent FDA warning letters for unlawful sale of unapproved and misbranded semaglutide.4,5 US poison centers have reported a 1500% increase in calls related to semaglutide, highlighting the need for enhanced pharmacovigilance including for online sourcing harms.6 Study limitations include limited sample of products tested due to nondelivery scams. Furthermore, although tested products represent some accessible semaglutide products sold online, higher priced offerings were excluded, limiting generalizability of the findings."

Study Finds GLP-1s Are Effectively Over-the-Counter Drugs in Online Grey Market | Cato at Liberty Blog






No comments: